Menu
Close
About Us
Company Overview
Our History
Leadership
Board of Directors
Scientific Advisory Board
Our Advisors
Therapeutic Areas
Acute Myocarditis
Recurrent Pericarditis
Heart Failure
Research
R&D Partners
Our Science
Resources
Pipeline
CardiolRX™
Investors
Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
Corporate Governance
Contact Us
News
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure
March 07, 2023
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis
January 17, 2023
Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis
December 12, 2022
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
November 14, 2022
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis
November 07, 2022
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
October 25, 2022
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
October 03, 2022
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis
August 03, 2022
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
June 29, 2022
Page 1 of 11
1
2
3
4
5
...
10
...
»
Last »
